Home / Deep Research / Epidermolysis Bullosa

Epidermolysis Bullosa

1. Disease Information (definitions and current understanding)

2026-05-08
Falcon MONDO:0006541 Model: Edison Scientific Literature 51 citations

1. Disease Information (definitions and current understanding)

Concise disease overview

EB is an inherited, heterogeneous group of rare genetic dermatoses characterized by mucocutaneous fragility and blister formation that can be triggered by minimal mechanical trauma (bardhan2020epidermolysisbullosa pages 1-2). A widely used framing is that EB comprises >30 subtypes grouped into four major categories—EB simplex, junctional EB, dystrophic EB, and Kindler EB—defined primarily by the plane of tissue cleavage within the skin, reflecting the underlying molecular defect (bardhan2020epidermolysisbullosa pages 1-2).

Key definitional quote (from abstract-style text)

Classification (consensus framing)

2. Etiology

Disease causal factors

EB is primarily caused by germline pathogenic variants in genes encoding structural proteins required for epithelial integrity and epidermal–dermal adhesion. A major review notes “pathogenetic mutations in 16 distinct genes” implicated in EB (bardhan2020epidermolysisbullosa pages 1-2). A 2024 review similarly states EB-causing mutations can be present in at least 16 different genes (bischof2024emerginggenetherapeutics pages 1-2).

Genetic risk factors (causal genes by major EB type)

Causal genes are subtype-dependent. Examples explicitly present in the retrieved evidence include: - EBS: KRT5, KRT14, PLEC (with a statement that “75% of patients with EB simplex harbour mutations” in KRT5/KRT14) (bardhan2020epidermolysisbullosa pages 6-7) - JEB: LAMA3, LAMB3, LAMC2, ITGA6/ITGB4 (integrin α6β4), COL17A1 (type XVII collagen) (bardhan2020epidermolysisbullosa pages 4-5, bischof2024emerginggenetherapeutics pages 1-2) - DEB: COL7A1 (type VII collagen) (bardhan2020epidermolysisbullosa pages 10-11) - Kindler EB: FERMT1 (also referred to as KIND1 in some texts) (bischof2024emerginggenetherapeutics pages 1-2, suru2024epidemiologicalcharacteristicsof pages 4-6)

OpenTargets also lists strong gene–disease associations for EB consistent with these causal genes (e.g., COL7A1, KRT5) (OpenTargets Search: Epidermolysis bullosa).

Variant classes and functional consequences (examples from retrieved evidence)

For DEB, COL7A1 variant class influences phenotype: - Recessive COL7A1 mutations often include premature termination codons causing reduced mRNA and markedly reduced/absent type VII collagen (loss-of-function) (bardhan2020epidermolysisbullosa pages 10-11). - Non-terminating variants (example: glycine substitutions) can impair collagen triple helix assembly and are associated with milder disease in some cases (bardhan2020epidermolysisbullosa pages 10-11).

Environmental risk and protective factors

EB is genetic in origin; environmental factors primarily modify clinical severity (e.g., mechanical trauma/friction provoking blistering) rather than cause disease onset (bardhan2020epidermolysisbullosa pages 1-2, bischof2024emerginggenetherapeutics pages 1-2). Specific protective environmental factors are not well characterized in the retrieved evidence.

Gene–environment interactions

The defining clinical trigger is mechanical trauma acting on genetically fragile skin, producing blistering and chronic wounds; this is inherent to the classification by tissue cleavage plane and the “minimal trauma” definition (bardhan2020epidermolysisbullosa pages 1-2, bischof2024emerginggenetherapeutics pages 1-2).

3. Phenotypes (with HPO suggestions)

Core mucocutaneous phenotype (all major types)

Dystrophic EB / severe RDEB phenotype cluster

Severe RDEB is characterized by chronic, painful wounds and fibrotic scarring leading to deformity and strictures, including: - Pseudosyndactyly / mitten deformities (HPO: Syndactyly [HP:0001159] / Cutaneous syndactyly [HP:0010692]) (sandoval2025towardsextracellularvesicles pages 1-2). - Microstomia (HPO: Microstomia [HP:0000212]) and esophageal strictures (HPO: Esophageal stricture [HP:0002044]) (sandoval2025towardsextracellularvesicles pages 1-2). - High risk of aggressive cutaneous squamous cell carcinoma (cSCC) (HPO: Squamous cell carcinoma [HP:0002860]) (hwang2024therapiesforcutaneous pages 1-3).

Itch: phenotype frequency and QoL association (human prospective registry; 2023)

A large, prospective registry study in RDEB (PEBLES; 50 participants, 243 reviews) found itch is highly prevalent and severe: - Quote: “Itch was frequent, present in the preceding month in 93% of reviews.” (Aug 2023; URL: https://doi.org/10.1186/s13023-023-02817-z) (mellerio2023itchinrecessive pages 1-2). - Subtype differences: itch frequency (“always/often”) was 87% in severe RDEB reviews vs 42% in intermediate RDEB reviews; RDEB-pruriginosa had particularly high itch burden (mellerio2023itchinrecessive pages 4-6). - Medication use: 61% of reviews reported itch medication use; at index, oral antihistamines 28% and emollients 24% (mellerio2023itchinrecessive pages 6-7). - Correlations with disease severity and QoL scores depended on subtype: correlations were present in intermediate/inversa forms but weak in severe RDEB (mellerio2023itchinrecessive pages 1-2, mellerio2023itchinrecessive pages 6-7).

Quality-of-life impact (recent quantitative data; 2024)

A Spanish societal-burden study (2024; reference year 2022) reports large HRQoL impairment measured by EQ-5D: - Mean EQ-5D utility index: 0.45 for severe EB vs 0.62 for non-severe EB (proxy/self reporting differences described) (arandareneo2024economicburdenand pages 1-2, arandareneo2024economicburdenand pages 6-7).

4. Genetic / Molecular Information

Causal genes (core set in retrieved evidence)

EB is genetically heterogeneous; causal genes explicitly supported in the retrieved evidence include: - EBS: KRT5, KRT14, PLEC (bischof2024emerginggenetherapeutics pages 1-2, bardhan2020epidermolysisbullosa pages 6-7) - JEB: LAMA3, LAMB3, LAMC2, ITGA6/ITGB4, COL17A1 (bardhan2020epidermolysisbullosa pages 4-5, bischof2024emerginggenetherapeutics pages 1-2) - DEB: COL7A1 (bardhan2020epidermolysisbullosa pages 10-11) - Kindler EB: FERMT1 (suru2024epidemiologicalcharacteristicsof pages 4-6)

Inheritance patterns

A Romanian population-based study (2012–2024) reported inheritance patterns among its cohort (not all specified): autosomal recessive (58), autosomal dominant (29), de novo (3), unspecified (62) (suru2024epidemiologicalcharacteristicsof pages 4-6). Dystrophic EB may be autosomal dominant, autosomal recessive, or de novo (bardhan2020epidermolysisbullosa pages 10-11).

Functional biology summary (protein dysfunction)

EB phenotypes reflect failure of key structural proteins in keratinocyte cytoskeleton (EBS), hemidesmosomes/basement membrane zone (JEB), or anchoring fibrils (DEB). For example, dystrophic EB is “characterized by cleavage in the upper dermis” and “arising in all cases from COL7A1 mutations” with disrupted type VII collagen anchoring fibrils (bardhan2020epidermolysisbullosa pages 10-11).

Modifier genes, epigenetics, chromosomal abnormalities

Not specifically described in the retrieved evidence; additional targeted searches (ClinGen/ClinVar/GWAS/epigenomic datasets) would be required for robust modifier and epigenetic annotation.

5. Environmental Information

6. Mechanism / Pathophysiology (causal chains, upstream vs downstream)

Canonical mechanistic chain

  1. Germline pathogenic variant(s) in skin adhesion/structural genes (e.g., COL7A1, LAMB3, KRT5/KRT14). (Upstream cause) (bardhan2020epidermolysisbullosa pages 1-2, bardhan2020epidermolysisbullosa pages 10-11)
  2. Loss/dysfunction of adhesion structures at a specific ultrastructural level (intraepidermal; lamina lucida; sublamina densa; mixed). (Core molecular defect) (bardhan2020epidermolysisbullosa pages 1-2, bischof2024emerginggenetherapeutics pages 1-2)
  3. Mechanical trauma → epidermal–dermal separation → blisters/erosions. (Trigger-to-lesion mechanism) (bardhan2020epidermolysisbullosa pages 1-2, bischof2024emerginggenetherapeutics pages 1-2)
  4. Chronic wounds + inflammation + fibrosis/scarring → deformities (pseudosyndactyly), strictures, nutritional compromise, anemia; high risk of aggressive cSCC especially in severe RDEB. (Downstream complications) (sandoval2025towardsextracellularvesicles pages 1-2, hwang2024therapiesforcutaneous pages 1-3, bardhan2020epidermolysisbullosa pages 5-6)

Cellular and tissue structures (ontology suggestions)

  • GO biological processes (examples): cell adhesion, extracellular matrix organization, wound healing, inflammatory response, keratinocyte differentiation.
  • CL cell types (examples): keratinocyte (CL:0000312), fibroblast (CL:0000057), immune cells relevant to wound inflammation (e.g., macrophage CL:0000235).
  • Subcellular / structural components (GO cellular component examples): basement membrane (GO:0005604), hemidesmosome (GO:0030056), intermediate filament (GO:0005882).

Squamous cell carcinoma as a major downstream mechanism

A major EB review identifies SCC as a feared complication and leading cause of mortality (bardhan2020epidermolysisbullosa pages 1-2). A 2024 systematic review in RDEB-cSCC quantifies high cumulative incidence and mortality, consistent with aggressive malignant transformation in chronic wound environments (hwang2024therapiesforcutaneous pages 1-3).

7. Anatomical Structures Affected (with UBERON/CL suggestions)

Organ and system level

Tissue and cell level

  • Tissues: epidermis, dermis, basement membrane zone / dermal–epidermal junction (bischof2024emerginggenetherapeutics pages 1-2).
  • Cells: basal keratinocytes (EBS), epithelial cells forming hemidesmosomes and basement membrane attachments, dermal fibroblasts contributing to fibrosis and scarring.

Localization and laterality

Not specifically emphasized in the retrieved evidence; generally widespread (generalized types) vs localized (e.g., localized EBS) distributions occur (suru2024epidemiologicalcharacteristicsof pages 4-6).

8. Temporal Development (onset, progression, staging)

Onset

EB often manifests at birth or in early infancy, particularly in severe subtypes; RDEB is noted to typically manifest at birth (sandoval2025towardsextracellularvesicles pages 1-2).

Progression and natural history

Course depends on subtype and severity. Examples from Eastern European registry-style data: - Romanian cohort had substantial pediatric representation, but also adult survival depending on type/subtype (suru2024epidemiologicalcharacteristicsof pages 6-9). - Russian pediatric registry data show substantial early mortality in junctional forms, with survival probability dropping “almost to 0% in the first 100 days” for junctional congenital EB (murashkin2024congenitalepidermolysisbullosa pages 1-2).

9. Inheritance and Population

Epidemiology (recent registry-derived estimates, prioritizing 2024)

Romania (2012–2024; point reference 31 Dec 2023): - Point prevalence: 6.77 per million population; incidence: 24.23 per million live births (Jun 2024; URL: https://doi.org/10.3390/jcm13133742) (suru2024epidemiologicalcharacteristicsof pages 1-2). - Major type distribution: EBS 21%, JEB 3%, DEB 63%, KEB 2%, EB NOS 11% (suru2024epidemiologicalcharacteristicsof pages 1-2). - Sex distribution reported as slight female preponderance (approx. 52% vs 48%) (suru2024epidemiologicalcharacteristicsof pages 6-9).

Russian Federation children (registry as of 2024; ages 0–17): - Pediatric prevalence: 15.48 per 1,000,000 children; sex ratio boys:girls 1.08:1 (Oct 2024; URL: https://doi.org/10.15690/vsp.v23i5.2808) (murashkin2024congenitalepidermolysisbullosa pages 1-2). - Type counts among 491 children: dystrophic 261, simplex 191, junctional 31, Kindler 8 (murashkin2024congenitalepidermolysisbullosa pages 1-2). - Five-year mean birth rate: 2.13 per 100,000 births (2019–2023) (murashkin2024congenitalepidermolysisbullosa pages 1-2). - Mortality: 22 deaths recorded; junctional accounts for 59.1% of deaths; highest mortality in age 0–1 years (65.2% of deaths) with sepsis-related multi-organ failure noted as leading cause (murashkin2024congenitalepidermolysisbullosa pages 1-2).

Founder effects/consanguinity

The Russian registry highlights a high-burden region (Dagestan) with “apparently” high consanguineous marriage rates (50%) corresponding to higher case counts, suggesting a role for autosomal recessive inheritance and local population structure (murashkin2024congenitalepidermolysisbullosa pages 2-3).

10. Diagnostics

Diagnostic workflow (current standard framing)

A major authoritative review emphasizes that precise diagnosis relies on correlating: - Clinical phenotype, plus - Electron microscopy and immunohistological features (including immunofluorescence mapping), plus - Mutational analyses (genetic testing) (bardhan2020epidermolysisbullosa pages 1-2).

Real-world diagnostic utilization (Romania 2012–2024)

In the Romanian cohort: - 83/152 (54.6%) were clinically diagnosed only. - 48 (31.5%) had molecular genetic testing. - Smaller fractions had IF mapping (IFM) and/or transmission electron microscopy (TEM), including 2 with IFM+TEM and additional cases combining IFM or TEM with genetics (suru2024epidemiologicalcharacteristicsof pages 4-6).

Differential diagnosis

Not specifically enumerated in the retrieved evidence; standard differentials include acquired blistering diseases and other skin fragility syndromes—note that the Romanian study explicitly excluded acquired EB and other fragility syndromes (suru2024epidemiologicalcharacteristicsof pages 2-4).

11. Outcome / Prognosis (including key statistics)

cSCC risk and outcomes in RDEB (2024 systematic review; 157 cases)

A 2024 systematic review of 157 RDEB-cSCC cases reports: - Cumulative risk for at least one cSCC: 7.5% by age 20 rising to 80% by age 45 (May 2024; URL: https://doi.org/10.1186/s13023-024-03190-1) (hwang2024therapiesforcutaneous pages 1-3). - Mortality estimates: 38.7% by 35 years, 70% by 40, 78.7% by 55 (hwang2024therapiesforcutaneous pages 1-3). - Tumor features: well-differentiated 64.1%, ulcerated 59.6%, ≥2 cm 77.6%; median age at diagnosis 30 years (hwang2024therapiesforcutaneous pages 1-3).

Survival variation by EB type (2024 Romania)

Romanian survival analysis indicated poorer survival for JEB and unspecified cases compared to other types (Kaplan–Meier curves shown; see extracted figure) (suru2024epidemiologicalcharacteristicsof media bf76e012).

12. Treatment (current applications, real-world implementations, and 2023–2024 developments)

Standard of care: supportive, multidisciplinary management

In the absence of universally curative therapy, management focuses on minimizing blister formation, wound care, symptom relief, and management of complications (including SCC) (bardhan2020epidermolysisbullosa pages 1-2).

FDA-approved topical gene therapy for DEB (major 2023 milestone)

A 2024 review of EB gene therapeutics describes the first approved in vivo topical gene replacement product: - Mechanism: HSV-1–based topical vector delivering functional COL7A1 to wounds (bischof2024emerginggenetherapeutics pages 8-9). - Phase III (GEM-3; NCT04491604; intrapatient matched wound pairs, n=31) outcomes: 71% complete wound closure at 3 months and 67% at 6 months vs placebo ~20–22% (bischof2024emerginggenetherapeutics pages 8-9, prodinger2024neuelokalund pages 1-2). - This product is widely referenced as Vyjuvek (beremagene geperpavec, B-VEC) and described as FDA approved in 2023 (prodinger2024neuelokalund pages 1-2, sandoval2025towardsextracellularvesicles pages 2-4).

Implementation and payer impact (2024 economic evaluation)

Post-approval economic modeling estimates substantial payer impact in the US: - Assumed base-case annual price $300,000 per patient per year. - Estimated first-year total expenditure $268 million (and the therapy described as weekly lifelong administration in the summarized source) (sandoval2025towardsextracellularvesicles pages 2-4).

Itch symptom management (2023 prospective registry evidence)

Despite frequent use of emollients and antihistamines, itch remains an unmet need in RDEB; only 61% of reviews reported using medication and satisfaction was low-moderate (mean 41.3/100) (mellerio2023itchinrecessive pages 6-7).

Treatment of RDEB-associated cSCC (2024 systematic review)

Surgery remains the primary modality, with emerging use of anti-EGFR therapy and immunotherapy in advanced disease: - Median survival from first cSCC diagnosis to death varied by regimen (e.g., ~2 years for surgery only; ~4–4.6 years with addition of anti-EGFR or immunotherapy in small subsets) (hwang2024therapiesforcutaneous pages 1-3).

Other approved therapies

  • Filsuvez (Oleogel-S10) is noted in recent reviews as an approved therapy for EB wound healing support, but detailed trial-level quantitative outcomes were not available in the retrieved evidence set here and should be curated from primary regulatory documents and pivotal trial publications (sandoval2025towardsextracellularvesicles pages 1-2).

MAXO suggestions (examples)

  • Gene therapy, topical administration: gene therapy procedure; topical administration of therapeutic agent.
  • Wound care: wound dressing, wound debridement (when applicable), pain management, pruritus management.
  • cSCC: surgical excision, radiotherapy, systemic chemotherapy, epidermal growth factor receptor inhibitor therapy, immune checkpoint inhibitor therapy.

13. Prevention

For a Mendelian disease, prevention focuses on genetic counseling and reproductive planning. The retrieved evidence set does not provide detailed guideline statements for prenatal testing/PGT/cascade testing; however, the importance of precise molecular diagnosis for genetic counseling and stratification is emphasized (bardhan2020epidermolysisbullosa pages 2-3).

Tertiary prevention is central in practice (e.g., preventing infections, malnutrition, contractures, strictures, and early detection of cSCC) (bardhan2020epidermolysisbullosa pages 1-2, hwang2024therapiesforcutaneous pages 1-3).

14. Other Species / Natural Disease

Not addressed in the retrieved evidence set.

15. Model Organisms

Not addressed in the retrieved evidence set.

Key structured summaries (artifacts)

The following tables summarize subtype genetics/features and the most evidence-supported 2023–2024 treatment landscape.

Table (click to expand)
EB type Primary cleavage level / skin layer Core causal genes mentioned in retrieved evidence Typical inheritance Hallmark clinical features Major complications Supporting context
Epidermolysis bullosa simplex (EBS) Intraepidermal cleavage within basal keratinocytes / epidermis KRT5, KRT14, PLEC Usually autosomal dominant; some autosomal recessive forms Skin fragility and trauma-induced blistering, often from birth or infancy; may include inflammation, failure to thrive, itch, neuropathic pain; some PLEC-associated forms have muscular dystrophy Variable severity; multisystem involvement in some forms (bardhan2020epidermolysisbullosa pages 1-2, bischof2024emerginggenetherapeutics pages 1-2, bardhan2020epidermolysisbullosa pages 6-7, suru2024epidemiologicalcharacteristicsof pages 4-6)
Junctional EB (JEB) Cleavage within the lamina lucida of the dermal-epidermal junction / basement membrane zone LAMA3, LAMB3, LAMC2, ITGA6, ITGB4, COL17A1 Mostly autosomal recessive Severe mucocutaneous fragility with blistering and erosions; some forms show exuberant granulation tissue, airway and upper GI involvement In severe JEB, high infant mortality; failure to thrive, sepsis, respiratory failure, cardiomyopathy; laryngeal disease can cause respiratory compromise and death (bardhan2020epidermolysisbullosa pages 1-2, bardhan2020epidermolysisbullosa pages 4-5, bischof2024emerginggenetherapeutics pages 1-2, bardhan2020epidermolysisbullosa pages 6-7)
Dystrophic EB, dominant (DDEB) Sublamina densa / upper dermis, due to anchoring fibril dysfunction COL7A1 Autosomal dominant Trauma-induced blistering with scarring; generally milder than severe recessive disease; nail and mucosal involvement may occur Chronic wounds and scarring; cancer risk lower than severe RDEB but elevated in some patients (bardhan2020epidermolysisbullosa pages 4-5, bardhan2020epidermolysisbullosa pages 10-11, suru2024epidemiologicalcharacteristicsof pages 4-6)
Dystrophic EB, recessive (RDEB) Sublamina densa / upper dermis, due to absent or markedly reduced type VII collagen anchoring fibrils COL7A1 Autosomal recessive Congenital or early-onset severe blistering, chronic wounds, scarring, mitten deformities/pseudosyndactyly, microstomia, esophageal strictures, pain and itch Aggressive cutaneous squamous cell carcinoma is the leading cause of death in adults with severe RDEB; also anemia, malnutrition, renal disease, infection/sepsis, fibrosis (hwang2024therapiesforcutaneous pages 1-3, bardhan2020epidermolysisbullosa pages 5-6, bardhan2020epidermolysisbullosa pages 10-11, murashkin2024congenitalepidermolysisbullosa pages 2-3)
Kindler EB / Kindler syndrome Mixed and variable cleavage planes across multiple skin levels FERMT1 (KIND1) Autosomal recessive Skin fragility, blistering, and photosensitivity beginning in early childhood; progressive poikiloderma may occur Mucosal disease and later epithelial malignancies including non-melanoma skin cancer/SCC in adults (bardhan2020epidermolysisbullosa pages 1-2, bischof2024emerginggenetherapeutics pages 1-2, bardhan2020epidermolysisbullosa pages 10-11, suru2024epidemiologicalcharacteristicsof pages 4-6)

Table: This table summarizes the major epidermolysis bullosa types by tissue cleavage level, core genes, inheritance, hallmark clinical features, and major complications. It is designed as a compact ontology-ready overview for quick reference in a disease knowledge base.

Table (click to expand)
Intervention Target EB subtype Mechanism Regulatory status Key study/trial + date Key quantitative outcomes Notes/limitations Supporting context IDs
Beremagene geperpavec (B-VEC; Vyjuvek) Dystrophic EB, especially COL7A1-related DEB/RDEB Topical HSV-1–based in vivo gene replacement delivering functional COL7A1 to wounded skin FDA approved May 2023; EMA approval noted in 2025 sources GEM-3 phase 3, randomized intra-patient matched wound-pair trial, NCT04491604; weekly topical treatment for 26 weeks; NEJM trial cited from 2022; FDA approval noted 2023 Complete wound closure with B-VEC: 71% at 3 months and 67% at 6 months vs placebo 20–22%; phase 1/2: 17/18 wounds completely closed at 3 months; median time to closure 13.5 vs 22.5 days; mean duration of closure 103 vs 16.5 days Paired-lesion design; repeated application required; topical HSV vector does not penetrate intact skin well; safety profile mainly mild-moderate AEs, and serious AEs in later summaries were not attributed to product (bischof2024emerginggenetherapeutics pages 8-9, prodinger2024neuelokalund pages 1-2, NCT04491604 chunk 1, lisinska2025genetherapiesin pages 2-4) (bischof2024emerginggenetherapeutics pages 8-9, prodinger2024neuelokalund pages 1-2, NCT04491604 chunk 1, lisinska2025genetherapiesin pages 2-4)
B-VEC open-label extension Dystrophic EB previously treated or treatment-naive Continued topical COL7A1 gene replacement Post-approval/extension evidence; not a separate approval Open-label extension NCT04917874; published 2025, rollover + treatment-naive participants 47 subjects; treatment up to 112 weeks (median 81 weeks); maintained wound closure in rollover subjects ranged 61.1–89.5% through month 12; no new safety signals detected Open-label, variable follow-up, exploratory PROs inconclusive for QoL; publication is 2025 but highly relevant for real-world durability/safety (marinkovich2025longtermsafetyand pages 1-2)
Filsuvez (Oleogel-S10) EB wound healing support across inherited EB indications in recent reviews Topical birch triterpene oleogel intended to support re-epithelialization/wound healing Recently approved; referenced as approved in 2022–2024 reviews Mentioned in 2024–2025 EB therapeutic reviews Detailed quantitative trial outcomes not present in current retrieved evidence Should be included as a recent approved therapy, but the present evidence base here does not provide trial-level numeric endpoints; avoid overclaiming (sandoval2025towardsextracellularvesicles pages 1-2, prodinger2024neuelokalund pages 1-2)
Supportive care / itch management (PEBLES registry) Recessive dystrophic EB subtypes (RDEB-S, RDEB-I, RDEB-Inv, RDEB-Pru) Symptom control with emollients, topical corticosteroids, antihistamines and related anti-pruritic measures Standard supportive care; no disease-modifying approval claim PEBLES prospective register study, published 2023 Itch present in preceding month in 93% of 243 reviews from 50 participants; 61% of reviews reported itch medication use; at index, emollients 12/50 (24%), oral antihistamines 14/50 (28%); mean medication satisfaction 41.3/100 Strong evidence of unmet need: frequent itch, greater severity/distress in RDEB-S and RDEB-Pru, limited perceived efficacy of current medications (mellerio2023itchinrecessive pages 1-2, mellerio2023itchinrecessive pages 6-7, mellerio2023itchinrecessive pages 4-6, mellerio2023itchinrecessive pages 2-4)
cSCC treatment in RDEB: surgery, anti-EGFR therapy, immunotherapy RDEB-associated cutaneous squamous cell carcinoma Oncologic local/systemic treatment after malignant transformation; anti-EGFR or immune checkpoint blockade used in advanced disease No EB-specific regulatory approval summarized here; used in practice based on cSCC management Systematic review of 157 cases, published 2024 Median survival from first cSCC diagnosis to death: 2.0 years (surgery only), 4.0 years (+anti-EGFR), 4.6 years (+immunotherapy), 1.85 years (surgery+chemotherapy), 4.0 years (surgery+radiotherapy), 9.5 years (surgery+chemotherapy+radiotherapy; very small n); surgery was primary treatment in 128 cases Evidence mostly case reports/cohorts, major confounding by multimodal treatment and small sample sizes; adverse events included impaired wound healing with immunotherapy and nausea/fatigue with anti-EGFR therapy (hwang2024therapiesforcutaneous pages 1-3)
Health-system implementation: projected B-VEC spending US DEB population eligible for B-VEC Economic implementation analysis rather than biologic mechanism Reflects post-approval payer impact after FDA approval JAMA Dermatology economic evaluation, 2024 Estimated 894 US DEB patients eligible in year 1; projected spending $268 million first year and $805 million over 3 years; assumed base-case cost $300,000/patient/year; lifetime total cost estimated $15–17 million/patient Important for real-world access and reimbursement; FDA indication included both AR and AD DEB, with limited direct trial data in dominant disease noted by authors (sandoval2025towardsextracellularvesicles pages 2-4)

Table: This table summarizes the most clinically relevant epidermolysis bullosa therapies and management strategies emphasized in the retrieved 2023-2024 evidence, including approved gene therapy, supportive care, and cSCC treatment. It is useful for quickly comparing mechanisms, regulatory status, quantitative outcomes, and implementation caveats.

Notes on evidence limitations and curation gaps

  1. OMIM/Orphanet/ICD/MeSH identifiers were not directly retrievable via the current tool calls; they should be added from those resources in a follow-on curation pass.
  2. Several key topics requested for a knowledge base entry (modifier genes, epigenetics, model organisms, comparative disease in animals, and detailed prevention/genetic screening guidelines) are not covered by the retrieved documents and require targeted additional retrieval.
  3. For Filsuvez (Oleogel-S10), the present evidence confirms it as a recently approved therapy in reviews but does not provide pivotal-trial effect sizes; primary trial publications/regulatory assessments should be cited before adding numeric claims.

Included URLs and publication dates (selected high-value sources)

References

  1. (OpenTargets Search: Epidermolysis bullosa): Open Targets Query (Epidermolysis bullosa, 30 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  2. (bardhan2020epidermolysisbullosa pages 1-2): Ajoy Bardhan, Leena Bruckner-Tuderman, Iain L. C. Chapple, Jo-David Fine, Natasha Harper, Cristina Has, Thomas M. Magin, M. Peter Marinkovich, John F. Marshall, John A. McGrath, Jemima E. Mellerio, Rex Polson, and Adrian H. Heagerty. Epidermolysis bullosa. Nature Reviews Disease Primers, 6:1-27, Sep 2020. URL: https://doi.org/10.1038/s41572-020-0210-0, doi:10.1038/s41572-020-0210-0. This article has 551 citations.

  3. (bischof2024emerginggenetherapeutics pages 1-2): Johannes Bischof, Markus Hierl, and Ulrich Koller. Emerging gene therapeutics for epidermolysis bullosa under development. International Journal of Molecular Sciences, 25:2243, Feb 2024. URL: https://doi.org/10.3390/ijms25042243, doi:10.3390/ijms25042243. This article has 37 citations.

  4. (hwang2024therapiesforcutaneous pages 1-3): Austin Hwang, Andie Kwon, Corinne H. Miller, Antonia Reimer-Taschenbrecker, and Amy S. Paller. Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases. Orphanet Journal of Rare Diseases, May 2024. URL: https://doi.org/10.1186/s13023-024-03190-1, doi:10.1186/s13023-024-03190-1. This article has 13 citations and is from a peer-reviewed journal.

  5. (suru2024epidemiologicalcharacteristicsof pages 6-9): Alina Suru, Sorina Dănescu, Alina Călinescu-Stîncanu, Denis Iorga, Mihai Dascălu, Adrian Baican, George-Sorin Țiplica, and Carmen Maria Sălăvăstru. Epidemiological characteristics of inherited epidermolysis bullosa in an eastern european population. Journal of Clinical Medicine, 13:3742, Jun 2024. URL: https://doi.org/10.3390/jcm13133742, doi:10.3390/jcm13133742. This article has 6 citations.

  6. (bardhan2020epidermolysisbullosa pages 6-7): Ajoy Bardhan, Leena Bruckner-Tuderman, Iain L. C. Chapple, Jo-David Fine, Natasha Harper, Cristina Has, Thomas M. Magin, M. Peter Marinkovich, John F. Marshall, John A. McGrath, Jemima E. Mellerio, Rex Polson, and Adrian H. Heagerty. Epidermolysis bullosa. Nature Reviews Disease Primers, 6:1-27, Sep 2020. URL: https://doi.org/10.1038/s41572-020-0210-0, doi:10.1038/s41572-020-0210-0. This article has 551 citations.

  7. (bardhan2020epidermolysisbullosa pages 4-5): Ajoy Bardhan, Leena Bruckner-Tuderman, Iain L. C. Chapple, Jo-David Fine, Natasha Harper, Cristina Has, Thomas M. Magin, M. Peter Marinkovich, John F. Marshall, John A. McGrath, Jemima E. Mellerio, Rex Polson, and Adrian H. Heagerty. Epidermolysis bullosa. Nature Reviews Disease Primers, 6:1-27, Sep 2020. URL: https://doi.org/10.1038/s41572-020-0210-0, doi:10.1038/s41572-020-0210-0. This article has 551 citations.

  8. (bardhan2020epidermolysisbullosa pages 10-11): Ajoy Bardhan, Leena Bruckner-Tuderman, Iain L. C. Chapple, Jo-David Fine, Natasha Harper, Cristina Has, Thomas M. Magin, M. Peter Marinkovich, John F. Marshall, John A. McGrath, Jemima E. Mellerio, Rex Polson, and Adrian H. Heagerty. Epidermolysis bullosa. Nature Reviews Disease Primers, 6:1-27, Sep 2020. URL: https://doi.org/10.1038/s41572-020-0210-0, doi:10.1038/s41572-020-0210-0. This article has 551 citations.

  9. (suru2024epidemiologicalcharacteristicsof pages 4-6): Alina Suru, Sorina Dănescu, Alina Călinescu-Stîncanu, Denis Iorga, Mihai Dascălu, Adrian Baican, George-Sorin Țiplica, and Carmen Maria Sălăvăstru. Epidemiological characteristics of inherited epidermolysis bullosa in an eastern european population. Journal of Clinical Medicine, 13:3742, Jun 2024. URL: https://doi.org/10.3390/jcm13133742, doi:10.3390/jcm13133742. This article has 6 citations.

  10. (mellerio2023itchinrecessive pages 1-2): Jemima E. Mellerio, Elizabeth I. Pillay, Lesedi Ledwaba-Chapman, Alessandra Bisquera, Susan J. Robertson, Marieta Papanikolaou, John A. McGrath, Yanzhong Wang, Anna E. Martinez, and Eunice Jeffs. Itch in recessive dystrophic epidermolysis bullosa: findings of pebles, a prospective register study. Orphanet Journal of Rare Diseases, Aug 2023. URL: https://doi.org/10.1186/s13023-023-02817-z, doi:10.1186/s13023-023-02817-z. This article has 14 citations and is from a peer-reviewed journal.

  11. (sandoval2025towardsextracellularvesicles pages 1-2): Aaron Gabriel W. Sandoval and Evangelos V. Badiavas. Towards extracellular vesicles in the treatment of epidermolysis bullosa. Bioengineering, 12:574, May 2025. URL: https://doi.org/10.3390/bioengineering12060574, doi:10.3390/bioengineering12060574. This article has 3 citations.

  12. (mellerio2023itchinrecessive pages 4-6): Jemima E. Mellerio, Elizabeth I. Pillay, Lesedi Ledwaba-Chapman, Alessandra Bisquera, Susan J. Robertson, Marieta Papanikolaou, John A. McGrath, Yanzhong Wang, Anna E. Martinez, and Eunice Jeffs. Itch in recessive dystrophic epidermolysis bullosa: findings of pebles, a prospective register study. Orphanet Journal of Rare Diseases, Aug 2023. URL: https://doi.org/10.1186/s13023-023-02817-z, doi:10.1186/s13023-023-02817-z. This article has 14 citations and is from a peer-reviewed journal.

  13. (mellerio2023itchinrecessive pages 6-7): Jemima E. Mellerio, Elizabeth I. Pillay, Lesedi Ledwaba-Chapman, Alessandra Bisquera, Susan J. Robertson, Marieta Papanikolaou, John A. McGrath, Yanzhong Wang, Anna E. Martinez, and Eunice Jeffs. Itch in recessive dystrophic epidermolysis bullosa: findings of pebles, a prospective register study. Orphanet Journal of Rare Diseases, Aug 2023. URL: https://doi.org/10.1186/s13023-023-02817-z, doi:10.1186/s13023-023-02817-z. This article has 14 citations and is from a peer-reviewed journal.

  14. (arandareneo2024economicburdenand pages 1-2): Isaac Aranda-Reneo, Juan Oliva-Moreno, Luz María Peña-Longobardo, Álvaro Rafael Villar-Hernández, and Julio López-Bastida. Economic burden and health-related quality of life in patients with epidermolysis bullosa in spain. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03328-1, doi:10.1186/s13023-024-03328-1. This article has 4 citations and is from a peer-reviewed journal.

  15. (arandareneo2024economicburdenand pages 6-7): Isaac Aranda-Reneo, Juan Oliva-Moreno, Luz María Peña-Longobardo, Álvaro Rafael Villar-Hernández, and Julio López-Bastida. Economic burden and health-related quality of life in patients with epidermolysis bullosa in spain. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03328-1, doi:10.1186/s13023-024-03328-1. This article has 4 citations and is from a peer-reviewed journal.

  16. (murashkin2024congenitalepidermolysisbullosa pages 1-2): Nikolay N. Murashkin, Roman V. Epishev, Olga S. Orlova, Alena А. Kuratova, and Victoriya S. Polenova. Congenital epidermolysis bullosa epidemiology among children of russian federation. Current Pediatrics, 23:316-328, Oct 2024. URL: https://doi.org/10.15690/vsp.v23i5.2808, doi:10.15690/vsp.v23i5.2808. This article has 2 citations.

  17. (bardhan2020epidermolysisbullosa pages 5-6): Ajoy Bardhan, Leena Bruckner-Tuderman, Iain L. C. Chapple, Jo-David Fine, Natasha Harper, Cristina Has, Thomas M. Magin, M. Peter Marinkovich, John F. Marshall, John A. McGrath, Jemima E. Mellerio, Rex Polson, and Adrian H. Heagerty. Epidermolysis bullosa. Nature Reviews Disease Primers, 6:1-27, Sep 2020. URL: https://doi.org/10.1038/s41572-020-0210-0, doi:10.1038/s41572-020-0210-0. This article has 551 citations.

  18. (suru2024epidemiologicalcharacteristicsof pages 1-2): Alina Suru, Sorina Dănescu, Alina Călinescu-Stîncanu, Denis Iorga, Mihai Dascălu, Adrian Baican, George-Sorin Țiplica, and Carmen Maria Sălăvăstru. Epidemiological characteristics of inherited epidermolysis bullosa in an eastern european population. Journal of Clinical Medicine, 13:3742, Jun 2024. URL: https://doi.org/10.3390/jcm13133742, doi:10.3390/jcm13133742. This article has 6 citations.

  19. (murashkin2024congenitalepidermolysisbullosa pages 2-3): Nikolay N. Murashkin, Roman V. Epishev, Olga S. Orlova, Alena А. Kuratova, and Victoriya S. Polenova. Congenital epidermolysis bullosa epidemiology among children of russian federation. Current Pediatrics, 23:316-328, Oct 2024. URL: https://doi.org/10.15690/vsp.v23i5.2808, doi:10.15690/vsp.v23i5.2808. This article has 2 citations.

  20. (suru2024epidemiologicalcharacteristicsof pages 2-4): Alina Suru, Sorina Dănescu, Alina Călinescu-Stîncanu, Denis Iorga, Mihai Dascălu, Adrian Baican, George-Sorin Țiplica, and Carmen Maria Sălăvăstru. Epidemiological characteristics of inherited epidermolysis bullosa in an eastern european population. Journal of Clinical Medicine, 13:3742, Jun 2024. URL: https://doi.org/10.3390/jcm13133742, doi:10.3390/jcm13133742. This article has 6 citations.

  21. (suru2024epidemiologicalcharacteristicsof media bf76e012): Alina Suru, Sorina Dănescu, Alina Călinescu-Stîncanu, Denis Iorga, Mihai Dascălu, Adrian Baican, George-Sorin Țiplica, and Carmen Maria Sălăvăstru. Epidemiological characteristics of inherited epidermolysis bullosa in an eastern european population. Journal of Clinical Medicine, 13:3742, Jun 2024. URL: https://doi.org/10.3390/jcm13133742, doi:10.3390/jcm13133742. This article has 6 citations.

  22. (bischof2024emerginggenetherapeutics pages 8-9): Johannes Bischof, Markus Hierl, and Ulrich Koller. Emerging gene therapeutics for epidermolysis bullosa under development. International Journal of Molecular Sciences, 25:2243, Feb 2024. URL: https://doi.org/10.3390/ijms25042243, doi:10.3390/ijms25042243. This article has 37 citations.

  23. (prodinger2024neuelokalund pages 1-2): Christine Prodinger and Martin Laimer. Neue lokal- und systemtherapien bei epidermolysis bullosa. hautnah, 23:43-49, Feb 2024. URL: https://doi.org/10.1007/s12326-024-00627-z, doi:10.1007/s12326-024-00627-z. This article has 1 citations.

  24. (sandoval2025towardsextracellularvesicles pages 2-4): Aaron Gabriel W. Sandoval and Evangelos V. Badiavas. Towards extracellular vesicles in the treatment of epidermolysis bullosa. Bioengineering, 12:574, May 2025. URL: https://doi.org/10.3390/bioengineering12060574, doi:10.3390/bioengineering12060574. This article has 3 citations.

  25. (bardhan2020epidermolysisbullosa pages 2-3): Ajoy Bardhan, Leena Bruckner-Tuderman, Iain L. C. Chapple, Jo-David Fine, Natasha Harper, Cristina Has, Thomas M. Magin, M. Peter Marinkovich, John F. Marshall, John A. McGrath, Jemima E. Mellerio, Rex Polson, and Adrian H. Heagerty. Epidermolysis bullosa. Nature Reviews Disease Primers, 6:1-27, Sep 2020. URL: https://doi.org/10.1038/s41572-020-0210-0, doi:10.1038/s41572-020-0210-0. This article has 551 citations.

  26. (NCT04491604 chunk 1): Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB. Krystal Biotech, Inc.. 2020. ClinicalTrials.gov Identifier: NCT04491604

  27. (lisinska2025genetherapiesin pages 2-4): Wiktoria Lisińska, Patryk Cegiełka, Zuzanna Zalewska, Natalia Bien, Dorota Sobolewska-Sztychny, Joanna Narbutt, and Aleksandra Lesiak. Gene therapies in dermatological diseases: a breakthrough in treatment. International Journal of Molecular Sciences, 26:6592, Jul 2025. URL: https://doi.org/10.3390/ijms26146592, doi:10.3390/ijms26146592. This article has 0 citations.

  28. (marinkovich2025longtermsafetyand pages 1-2): M. Peter Marinkovich, Amy S. Paller, Shireen V. Guide, Mercedes E. Gonzalez, Anne W. Lucky, Işın Sinem Bağcı, Brittani Agostini, Kolleen Fitzgerald, Shijie Chen, Hubert Chen, Meghan M. Conner, and Suma M. Krishnan. Long-term safety and tolerability of beremagene geperpavec-svdt (b-vec) in an open-label extension study of patients with dystrophic epidermolysis bullosa. American Journal of Clinical Dermatology, 26:623-635, Apr 2025. URL: https://doi.org/10.1007/s40257-025-00942-y, doi:10.1007/s40257-025-00942-y. This article has 12 citations and is from a peer-reviewed journal.

  29. (mellerio2023itchinrecessive pages 2-4): Jemima E. Mellerio, Elizabeth I. Pillay, Lesedi Ledwaba-Chapman, Alessandra Bisquera, Susan J. Robertson, Marieta Papanikolaou, John A. McGrath, Yanzhong Wang, Anna E. Martinez, and Eunice Jeffs. Itch in recessive dystrophic epidermolysis bullosa: findings of pebles, a prospective register study. Orphanet Journal of Rare Diseases, Aug 2023. URL: https://doi.org/10.1186/s13023-023-02817-z, doi:10.1186/s13023-023-02817-z. This article has 14 citations and is from a peer-reviewed journal.